Key Takeaway
Retatrutide produced greater weight loss than semaglutide (Ozempic/Wegovy) in clinical trials, with participants losing up to 24.2% of body weight versus 15-17% with semaglutide. But retatrutide[1] isn't yet FDA approved.
Retatrutide produced significantly greater weight loss than semaglutide (the active ingredient in Ozempic and Wegovy) in clinical trials. Phase 2 data showed up to 24.2% body weight loss with retatrutide over 48 weeks, compared to 15 to 17% with semaglutide in its important trials. But retatrutide[1] isn't yet FDA approved and direct head-to-head comparison data is limited.
Detailed Explanation
Retatrutide and semaglutide work through different mechanisms. Semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) is a GLP-1 receptor agonist. It mimics a single gut hormone to reduce appetite, slow gastric emptying, and improve blood sugar control.
Retatrutide is a triple-agonist that targets three receptors: GLP-1, GIP, and glucagon. This broader mechanism is designed to suppress appetite through GLP-1 activity, enhance insulin sensitivity through GIP activity, and increase energy expenditure and fat burning through glucagon activity. The addition of the glucagon receptor is what distinguishes retatrutide from both semaglutide and tirzepatide.
Weight Loss Comparison
In the Phase 2 trial published in the New England Journal of Medicine (2023), retatrutide at its highest dose (12 mg) produced an average weight loss of 24.2% over 48 weeks. By comparison, the STEP trials for semaglutide 2.4 mg (Wegovy) showed average weight loss of approximately 15 to 17% over 68 weeks. Retatrutide[1] achieved more weight loss in a shorter time frame, though these were separate trials with different study populations.
Side Effect Profile
Both drugs share gastrointestinal side effects common to GLP-1 based therapies, including nausea, vomiting, diarrhea, and constipation. In the Phase 2 trial, retatrutide's side effects were generally consistent with what is seen with other incretin-based drugs. The full side effect profile will become clearer once Phase 3 data is available from larger, more diverse patient groups.
Important Context
Cross-trial comparisons have limitations. Differences in study design, patient demographics, trial duration, and dosing schedules make it difficult to draw definitive conclusions about superiority without a direct head-to-head trial. semaglutide has years of real-world safety and efficacy data, while retatrutide's data is limited to clinical trial settings.
What to Consider
- Ozempic is available now. retatrutide isn't. Semaglutide can be prescribed today through licensed healthcare providers, while retatrutide remains in clinical trials.
- More receptors doesn't automatically mean better for everyone. Individual response to weight loss medications varies based on genetics, metabolic profile, and health conditions.
- Long-term safety data favors semaglutide. Semaglutide has been studied and used clinically for years, providing a clearer picture of long-term safety than retatrutide currently offers.
- The glucagon component is novel. Retatrutide's glucagon receptor activation may provide benefits for liver fat reduction and energy expenditure, but this mechanism also requires careful study for potential risks.
- Your provider can help you choose. A physician-supervised evaluation considers your full health picture, not just headline weight loss numbers.
Related Questions
Frequently Asked Questions
How does retatrutide differ from semaglutide and tirzepatide?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, compared to semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP). This triple mechanism showed higher average weight loss in early clinical trials. For a complete cost breakdown, see our affordable GLP-1 options.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
What weight loss results has retatrutide shown in trials?
Phase 2 trial data published in the New England Journal of Medicine showed participants lost up to 24.2% of body weight at the highest dose over 48 weeks[1]. Phase 3 trials are evaluating these results in larger, more diverse patient populations.
When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials. If trial results are positive, Eli Lilly could submit for FDA approval as early as 2025-2026, with potential commercial availability following approval. Timelines are subject to change based on regulatory review.
Medical References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed | ClinicalTrials.gov | DOI]
Take the Next Step
You don't need to wait for retatrutide to start losing weight with physician-supervised therapy. FormBlends connects you with licensed providers who prescribe proven GLP-1 and peptide treatments available today. Start your free consultation to find the right treatment for your goals.